Celestial Therapeutics

San Diego, United States· Est. 2020

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Celestial Therapeutics is an early-stage biotech leveraging proprietary 'Stellar mRNA' and novel lipid platforms to develop next-generation antivirals, anti-inflammatories, and mRNA vaccines. The company's science is rooted in licensed technology from Harvard University and research from National Jewish Health, targeting a broad range of infectious, rare, and oncological diseases. With a seasoned founding team and backing from notable accelerators and partners like CEPI, Celestial is positioned in the high-growth mRNA and antiviral therapeutics space, though it remains in the pre-clinical development phase.

Infectious DiseasesRare DiseasesCancers

Technology Platform

Proprietary lipid platform and 'Stellar mRNA' platform. The Stellar mRNA technology, licensed from Harvard, involves encoding immunostimulatory RNA (isRNA) sequences within mRNA to enhance innate immune responses. The lipid platform is based on pulmonary surfactant chemistry for developing dual-modal antivirals/anti-inflammatories.

Opportunities

The company operates in the high-growth mRNA therapeutics and antiviral markets, with platforms that could offer improved safety and efficacy.

Partnerships with CEPI provide non-dilutive funding and validation in the critical area of pandemic preparedness.

The broad applicability of its platforms across infectious, rare, and oncological diseases allows for multiple shots on goal.

Risk Factors

The company is at a very early, pre-clinical stage with unvalidated platform technologies, carrying high technical and scientific risk.

It is pre-revenue and faces significant funding risk to advance its research.

It also operates in extremely competitive landscapes dominated by large, well-resourced companies.

Competitive Landscape

Celestial competes in the crowded and advanced mRNA technology space against leaders like Moderna, BioNTech/Pfizer, and CureVac, as well as numerous biotechs. Its antiviral/anti-inflammatory approach also faces competition from large pharma and biotech firms. Differentiation will require demonstrating clear superiority over existing LNP and mRNA design technologies.